Maximum funding
Alnylam Pharmaceuticals·Products & Services·3 segments
Breakdown
| Segment | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|
| HELIOS-B Phase 3 Clinical Trial | — | $70.00M | $70.00M |
| ALN-AGT Phase 2 Clinical Trial | — | $26.00M | $26.00M |
| ALN-AGT Phase 3 Clinical Trial | $18.00M | $6.00M | $12.00M |
| Total | — | $26.00M | $26.00M |
Segments
ALN-AGT Phase 2 Clinical TrialView metric
ALN-AGT Phase 3 Clinical TrialView metric
HELIOS-B Phase 3 Clinical TrialView metric